Male hormonal contraception
Human reproduction is a complex phenomenon remaining at the center of interest of many medical and extra-medical disciplines and the search for new contraceptive methods is an important part of research effort. The development of effective forms of male hormonal contraception (MHC) is one of the priorities of the World Health Organization (WHO Task Force on Methods of Regulation of Male Fertility). The principle of MHC consists in the suppression of spermatogenesis while preserving all other functional aspects of the male glands (especially the sexual functions, bone metabolism and lean muscle mass). It is possible to stop spermatogenesis by blocking gonadotrophin (FSH and LH) secretion by testosterone administration (isolated or in combination with other hormones). The currently existing variants of MHC are based on testosterone application (which has in the same time the role of substitutive treatment--the so-called androgen "add-back") either in monotherapy (oral, intramuscular, transdermal and subcutaneous form) or in combination with various progestins (levonorgestrel, norethisterone, desogestrel, eronogestrel, medroxyprogesterone), antiandrogens or GnRH analogues. The most promising, at present, seem to be the methods which use a combination of depot testosterone preparations with long-acting progestins. To what extent will the role of MHC be important in the future--this can only be judged after establishing their effectiveness, full reversibility, safe application, acceptability, and financial accessibility in clinical practice.
| Errataetall: |
CommentIn: Vnitr Lek. 2006 Nov;52(11):1010-1. - PMID 17165517 |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Vnitrni lekarstvi - 52(2006), 11 vom: 20. Nov., Seite 1077-84 |
| Sprache: |
Tschechisch |
|---|
| Weiterer Titel: |
Muzská hormonální antikoncepce |
|---|
| Beteiligte Personen: |
Porsová-Dutoit, I [VerfasserIn] |
|---|
| Themen: |
3XMK78S47O |
|---|
| Anmerkungen: |
Date Completed 15.02.2007 Date Revised 21.11.2013 published: Print CommentIn: Vnitr Lek. 2006 Nov;52(11):1010-1. - PMID 17165517 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM167155245 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM167155245 | ||
| 003 | DE-627 | ||
| 005 | 20231223112322.0 | ||
| 007 | tu | ||
| 008 | 231223s2006 xx ||||| 00| ||cze c | ||
| 028 | 5 | 2 | |a pubmed24n0557.xml |
| 035 | |a (DE-627)NLM167155245 | ||
| 035 | |a (NLM)17165528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a cze | ||
| 100 | 1 | |a Porsová-Dutoit, I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Male hormonal contraception |
| 246 | 3 | 3 | |a Muzská hormonální antikoncepce |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2007 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Vnitr Lek. 2006 Nov;52(11):1010-1. - PMID 17165517 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Human reproduction is a complex phenomenon remaining at the center of interest of many medical and extra-medical disciplines and the search for new contraceptive methods is an important part of research effort. The development of effective forms of male hormonal contraception (MHC) is one of the priorities of the World Health Organization (WHO Task Force on Methods of Regulation of Male Fertility). The principle of MHC consists in the suppression of spermatogenesis while preserving all other functional aspects of the male glands (especially the sexual functions, bone metabolism and lean muscle mass). It is possible to stop spermatogenesis by blocking gonadotrophin (FSH and LH) secretion by testosterone administration (isolated or in combination with other hormones). The currently existing variants of MHC are based on testosterone application (which has in the same time the role of substitutive treatment--the so-called androgen "add-back") either in monotherapy (oral, intramuscular, transdermal and subcutaneous form) or in combination with various progestins (levonorgestrel, norethisterone, desogestrel, eronogestrel, medroxyprogesterone), antiandrogens or GnRH analogues. The most promising, at present, seem to be the methods which use a combination of depot testosterone preparations with long-acting progestins. To what extent will the role of MHC be important in the future--this can only be judged after establishing their effectiveness, full reversibility, safe application, acceptability, and financial accessibility in clinical practice | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Contraceptive Agents, Male |2 NLM | |
| 650 | 7 | |a Spermatogenesis-Blocking Agents |2 NLM | |
| 650 | 7 | |a Testosterone |2 NLM | |
| 650 | 7 | |a 3XMK78S47O |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Vnitrni lekarstvi |d 1955 |g 52(2006), 11 vom: 20. Nov., Seite 1077-84 |w (DE-627)NLM000011363 |x 0042-773X |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2006 |g number:11 |g day:20 |g month:11 |g pages:1077-84 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2006 |e 11 |b 20 |c 11 |h 1077-84 | ||